Opipramol

Fun, Hoong‐Kun; Loh, Wan-Sin; Siddegowda, M. S.; Yathirajan, H. S.; Narayana, B.

doi:10.1107/s1600536811021131

Cited by 4 publications

(9 citation statements)

References 8 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it has pronounced D2-, 5-HT2-, and H1-blocking potential and high affinity to sigma receptors (sigma-1 and sigma-2). The crystal structure studies of opipramol dipicrate (Jasinski et al, 2010) and opipramol (Fun et al, 2011) have been reported. In view of the importance of opipramol, the paper reports the crystal structure of the title compound, (I).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Opipramolium fumarate

et al. 2011

Self Cite

View full text Add to dashboard Cite

In the crystal structure of the title salt {systematic name: 4-[3-(5H-dibenz[b,f]azepin-5-yl)propyl]-1-(2-hydroxyethyl)piperazin-1-ium (2Z)-3-carboxyprop-2-enoate}, C23H30N3O+·C4H3O4 −, the piperazine group in the opipramol cation is protonated at only one of the N atoms. In the cation, the dihedral angle between the two benzene rings is 53.5 (6)°. An extensive array of intermolecular O—H⋯O, O—H⋯N and N—H⋯O hydrogen bonds and weak intermolecular N—H⋯O, C—H⋯O and C—H⋯π interactions dominate the crystal packing.

show abstract

Section: Methodsmentioning

confidence: 99%

“…For the use of opipramol in the treatment of anxiety disorders, see: Moller et al (2001). For related structures, see: Fun et al (2011); Jasinski et al (2010). For standard bond lengths, see Allen et al (1987).…”

Section: Related Literaturementioning

confidence: 99%

Opipramolium fumarate

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…For applications of opipramol, see: Moller et al (2001). For related structures, see: Jasinski et al (2010); Fun et al (2011); Siddegowda, Butcher et al (2011); Siddegowda, Jasinski et al (2011); Swamy et al (2007). For graph-set analysis of hydrogen bonds, see: Etter et al (1990); Bernstein et al (1995).…”

Section: Related Literaturementioning

confidence: 99%

“…However, it has pronounced D2-, 5-HT2-, and H1-blocking potential and high affinity to sigma receptors (sigma-1 and sigma-2). The crystal structures of opipramol dipicrate (Jasinski et al, 2010), opipramol (Fun et al, 2011), opipramolium fumarate (Siddegowda, Butcher et al, 2011) and flupentixol dihydrochloride (Siddegowda, Jasinski et al, 2011) have been reported recently. In view of the importance of the title compound we herein report its molecular and crystal structure.…”

Section: S1 Commentmentioning

confidence: 99%

Opipramol dihydrochloride

Betz

Gerber

Siddaraju

et al. 2011

Acta Crystallogr E Struct Rep Online

View full text Add to dashboard Cite

The title compound (systematic name: 4-{3-[2-azatricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl]propyl}-1-(2-hydroxyethyl)piperazine-1,4-diium dichloride), C23H31N3O+·2Cl−, is the dihydrochloride of a piperazine derivative bearing a bulky 3-(5H-dibenz[b,f]azepin-5-yl)propyl substituent. Protonation took place on both N atoms of the piperazine unit. The diazacyclohexane ring adopts a chair conformation. N—H⋯Cl, O—H⋯Cl and C—H⋯Cl hydrogen bonding as well as C—H⋯O contacts connect the components into a three-dimensional network in the crystal. Two C—H⋯π contacts are also observed.

show abstract

“…It acts also as moderate dopamine D2, serotonin 5-HT2 and histamine H1 receptors antagonist and shows low anticholinergic activity. Opipramol has an anxiolytic, sedative and mood-improving effect, while it has less antidepressant properties [ 20 , 21 , 22 ]. When applied in the evening, it has sleep-improving effect [ 25 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

Consecutive Controlled Case Series on Effectiveness of Opipramol in Severe Sleep Bruxism Management—Preliminary Study on New Therapeutic Path

et al. 2021

View full text Add to dashboard Cite

Background: Sleep bruxism (SB) management aims to reduce the number and magnitude of bruxism episodes per hour of a patient’s sleep and, therefore, reduce the potentially negative clinical consequences. Opipramol belongs to the group of tricyclic antidepressants (TCAs) and is considered as an atypical TCA, as it acts primarily as a sigma receptor agonist. This study aimed to preliminarily determine the effectiveness of opipramol in the management of severe SB. Methods: A total of 19 otherwise healthy participants with severe SB diagnosed during stage I video polysomnography (vPSG) were subjected to an 8-week pharmacotherapy trial with a 100 mg bedtime daily dose of opipramol and were then analyzed by control stage II vPSG. Results: The participants included 14 females and 5 males, aged 20–47 years (mean ± standard deviation: 32.32 ± 8.12). A comparison of stage I and II vPSG recordings showed a decrease in all the studied SB parameters in 78.85% of participants. Only in a small group of participants (15.53%) was a non-significant increase of SB parameters observed. Conclusions: A single 100 mg dose of opipramol at bedtime seems to positively affect the reduction of SB in otherwise healthy individuals diagnosed with severe SB. However, the subject requires further research on a larger population including a control group.

show abstract

Opipramol

Cited by 4 publications

References 8 publications

Opipramolium fumarate

Opipramolium fumarate

Opipramol dihydrochloride

Consecutive Controlled Case Series on Effectiveness of Opipramol in Severe Sleep Bruxism Management—Preliminary Study on New Therapeutic Path

Contact Info

Product

Resources

About